We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Hormone Treatment Linked to Development of Aggressive Cancer

By LabMedica International staff writers
Posted on 06 Dec 2018
A team of cancer researchers has identified a gene that promotes the growth and spread of the most aggressive type of prostate cancer.

While many forms of prostate cancer require little or no treatment, the aggressive type that spreads to other parts of the body and resists hormone therapy is usually fatal with only a third of such patients living for five years after diagnosis.

Previous studies have shown that treatment of prostate cancer (PC) by androgen suppression promoted the emergence of aggressive variants that were androgen receptor (AR) independent. More...
In a paper published in the November 26, 2018, online edition of the journal Nature Medicine, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) identified the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC).

The ONECUT2 (one cut homeobox 2) gene encodes a member of the onecut family of transcription factors, which are characterized by a cut domain and an atypical homeodomain. The OC2 protein binds to specific DNA sequences and stimulates expression of target genes, including genes involved in melanocyte and hepatocyte differentiation.

In the current study, OC2 was found to act as a survival factor in mCRPC models, suppressing the AR transcriptional program by direct regulation of AR target genes. It also activated genes associated with neural differentiation and progression to lethal disease. Furthermore, OC2 was active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors.

Following up, the investigators identified the compound CSRM617, which counteracted the action of onecut2. They showed that CSRM617 significantly reduced the size of prostate cancer metastases in mice.

"We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said senior author Dr. Michael Freeman, professor of surgery and biomedical sciences at Cedars-Sinai Medical Center. "Our research suggested that onecut2 is a master regulator of lethal prostate cancer that may be a useful therapeutic target in up to a third of patients whose cancer spreads and evades hormone therapy."

Related Links:
Cedars-Sinai Medical Center


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.